229 related articles for article (PubMed ID: 35445839)
21. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
[TBL] [Abstract][Full Text] [Related]
22. Practical considerations for testing the effects of cannabidiol on human anxiety.
Leen-Feldner EW; Bynion TM; Gournay R; Bonn-Miller MO; Feldner MT
J Anxiety Disord; 2021 Aug; 82():102429. PubMed ID: 34058457
[TBL] [Abstract][Full Text] [Related]
23. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
24. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.
Linares IM; Zuardi AW; Pereira LC; Queiroz RH; Mechoulam R; Guimarães FS; Crippa JA
Braz J Psychiatry; 2019; 41(1):9-14. PubMed ID: 30328956
[TBL] [Abstract][Full Text] [Related]
25. Cannabidiol as a Potential Treatment for Anxiety Disorders.
Blessing EM; Steenkamp MM; Manzanares J; Marmar CR
Neurotherapeutics; 2015 Oct; 12(4):825-36. PubMed ID: 26341731
[TBL] [Abstract][Full Text] [Related]
26. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People.
Anderson LL; Doohan PT; Oldfield L; Kevin RC; Arnold JC; Berger M; Amminger GP; McGregor IS
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):525-533. PubMed ID: 34121064
[TBL] [Abstract][Full Text] [Related]
27. Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.
Dixon T; Cadenhead KS
Trials; 2023 Nov; 24(1):775. PubMed ID: 38037108
[TBL] [Abstract][Full Text] [Related]
28. The Impact of Cannabidiol on Human Brain Function: A Systematic Review.
Batalla A; Bos J; Postma A; Bossong MG
Front Pharmacol; 2020; 11():618184. PubMed ID: 33551817
[No Abstract] [Full Text] [Related]
29. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.
Lee JLC; Bertoglio LJ; Guimarães FS; Stevenson CW
Br J Pharmacol; 2017 Oct; 174(19):3242-3256. PubMed ID: 28268256
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial.
Crippa JAS; Zuardi AW; Guimarães FS; Campos AC; de Lima Osório F; Loureiro SR; Dos Santos RG; Souza JDS; Ushirohira JM; Pacheco JC; Ferreira RR; Mancini Costa KC; Scomparin DS; Scarante FF; Pires-Dos-Santos I; Mechoulam R; Kapczinski F; Fonseca BAL; Esposito DLA; Pereira-Lima K; Sen S; Andraus MH; Hallak JEC;
JAMA Netw Open; 2021 Aug; 4(8):e2120603. PubMed ID: 34387679
[TBL] [Abstract][Full Text] [Related]
31. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.
Melas PA; Scherma M; Fratta W; Cifani C; Fadda P
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668469
[TBL] [Abstract][Full Text] [Related]
32. Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults.
Arndt DL; de Wit H
Cannabis Cannabinoid Res; 2017; 2(1):105-113. PubMed ID: 28861510
[No Abstract] [Full Text] [Related]
33. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.
Campos AC; Moreira FA; Gomes FV; Del Bel EA; Guimarães FS
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3364-78. PubMed ID: 23108553
[TBL] [Abstract][Full Text] [Related]
34. The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol.
McCartney D; Benson MJ; Suraev AS; Irwin C; Arkell TR; Grunstein RR; Hoyos CM; McGregor IS
Hum Psychopharmacol; 2020 Sep; 35(5):e2749. PubMed ID: 32729120
[TBL] [Abstract][Full Text] [Related]
35. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial.
Hurd YL; Spriggs S; Alishayev J; Winkel G; Gurgov K; Kudrich C; Oprescu AM; Salsitz E
Am J Psychiatry; 2019 Nov; 176(11):911-922. PubMed ID: 31109198
[TBL] [Abstract][Full Text] [Related]
36. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
Bhattacharyya S; Morrison PD; Fusar-Poli P; Martin-Santos R; Borgwardt S; Winton-Brown T; Nosarti C; O' Carroll CM; Seal M; Allen P; Mehta MA; Stone JM; Tunstall N; Giampietro V; Kapur S; Murray RM; Zuardi AW; Crippa JA; Atakan Z; McGuire PK
Neuropsychopharmacology; 2010 Feb; 35(3):764-74. PubMed ID: 19924114
[TBL] [Abstract][Full Text] [Related]
37. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
38. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.
Fusar-Poli P; Allen P; Bhattacharyya S; Crippa JA; Mechelli A; Borgwardt S; Martin-Santos R; Seal ML; O'Carrol C; Atakan Z; Zuardi AW; McGuire P
Int J Neuropsychopharmacol; 2010 May; 13(4):421-32. PubMed ID: 19775500
[TBL] [Abstract][Full Text] [Related]
39. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
Martin-Santos R; Crippa JA; Batalla A; Bhattacharyya S; Atakan Z; Borgwardt S; Allen P; Seal M; Langohr K; Farré M; Zuardi AW; McGuire PK
Curr Pharm Des; 2012; 18(32):4966-79. PubMed ID: 22716148
[TBL] [Abstract][Full Text] [Related]
40. Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study.
Winton-Brown TT; Allen P; Bhattacharyya S; Borgwardt SJ; Fusar-Poli P; Crippa JA; Seal ML; Martin-Santos R; Ffytche D; Zuardi AW; Atakan Z; McGuire PK
Neuropsychopharmacology; 2011 Jun; 36(7):1340-8. PubMed ID: 21412224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
